var data={"title":"Zidovudine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zidovudine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7169?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">see &quot;Zidovudine: Drug information&quot;</a> and <a href=\"topic.htm?path=zidovudine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zidovudine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708846\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myopathy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of zidovudine has been associated with symptomatic myopathy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis/severe hepatomegaly:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination, including with zidovudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235151\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Retrovir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235152\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AZT;</li>\n      <li>Retrovir;</li>\n      <li>Retrovir (AZT)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056074\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleoside Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445305\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 infection, treatment</b> (HHS [pediatric] 2017): Use in combination with other antiretroviral agents. Standard neonatal doses may be excessive in premature neonates; careful clinical assessment, evaluation of hepatic and renal function, and review of concomitant medications should be performed prior to the final dose increase:<b> Note:</b> Use IV route only until oral therapy can be administered:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 2 mg/kg/dose every 12 hours; at 4 weeks of age, increase dose to 3 mg/kg/dose every 12 hours; at &gt;8 to 10 weeks of age, increase to 12 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 2 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 3 mg/kg/dose every 12 hours; at &gt;6 to 8 weeks of age, increase to 12 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Birth to PNA &le;4 weeks of age:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed: 4 mg/kg/dose every 12 hours for 4 weeks then increase dose (see PNA &gt;4 weeks dosing or infant dosing as appropriate)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fixed weight-band dosing: Continue for 4 weeks then increase dose (see PNA &gt;4 weeks dosing or infant dosing as appropriate)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">2 to &lt;3 kg: 10 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3 to &lt;4 kg: 15 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">4 to &lt;5 kg: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &gt;4 weeks of age: 12 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> The IV dose is 75% of the oral dose administered at the same interval</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 1.5 mg/kg/dose every 12 hours; at 4 weeks of age, increase dose to 2.3 mg/kg/dose every 12 hours; at &gt;8 to 10 weeks of age, increase to 9 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 1.5 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 2.3 mg/kg/dose every 12 hours; at &gt;6 to 8 weeks of age, increase to 9 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks: 3 mg/kg/dose every 12 hours; at &gt;4 weeks of age, increase to 9 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 perinatal transmission, prevention </b>(HHS [perinatal] 2017): Zidovudine dosing should begin as soon as possible after birth (within 6 to 12 hours after delivery). For patients at high risk of HIV acquisition, a 2- or 3-drug regimen may be needed. If neonate is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 2 mg/kg/dose every 12 hours; at 4 weeks of age, increase dose to 3 mg/kg/dose every 12 hours for 2 weeks for a total of 6 weeks zidovudine therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 2 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 3 mg/kg/dose every 12 hours for 4 weeks for a total of 6 weeks zidovudine therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks: Usual duration is 4 to 6 weeks. The shorter 4-week course is recommended if the mother received standard combination antiretroviral therapy during pregnancy, viral suppression was sustained, and maternal adherence is not a concern</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed weight-band dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2 to &lt;3 kg: 10 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3 to &lt;4 kg: 15 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">4 to &lt;5 kg: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> Use IV route only until oral therapy can be administered:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 1.5 mg/kg/dose every 12 hours; at 4 weeks of age, increase dose to 2.3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 1.5 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 2.3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks: 3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-1 nonoccupational (nonperinatal) postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 2 mg/kg/dose every 12 hours; at PNA 29 days, increase dose to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 2 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks: 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;30 weeks: 1.5 mg/kg/dose every 12 hours; at PNA 29 days, increase dose to 3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;30 weeks and &lt;35 weeks: 1.5 mg/kg/dose every 12 hours; at PNA 15 days, increase dose to 3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;35 weeks: 3 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for hematologic toxicity:</b> Consider interruption of therapy for significant anemia (neonates: HgB &lt;7 g/dL) and/or significant neutropenia (neonates ANC &lt;500 cells/mm<sup>3</sup>) until evidence of bone marrow recovery occurs; once bone marrow recovers, dose may be resumed using appropriate adjunctive therapy (eg, epoetin alfa) (HHS [pediatric] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056067\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">see &quot;Zidovudine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants born prematurely (PMA &lt;35 weeks) weighing &lt;4 kg: Refer to Dosing: Neonatal; standard infant doses may be excessive in infants who were born prematurely</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants (born at or near term with PMA &ge;35 weeks) weighing &ge;4 kg, Children, and Adolescents: <b>Note:</b> The 3-times-daily dosing is FDA approved but rarely used in practice; twice daily dosing is recommended in the current pediatric HIV guidelines (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">4 to &lt;9 kg: 12 mg/kg/dose twice daily <b>or</b> 8 mg/kg/dose 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">9 to &lt;30 kg: 9 mg/kg/dose twice daily <b>or</b> 6 mg/kg/dose 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;30 kg: 300 mg twice daily <b>or</b> 200 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA-directed dosing: 240 mg/<b>m<sup>2</sup></b>/dose every 12 hours, range: 180 to 240 mg/m<sup>2</sup>/dose every 12 hours (maximum dose: 300 mg/dose) or 160 mg/<b>m<sup>2</sup></b>/dose every 8 hours (maximum dose: 200 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: <b>Note:</b> Use IV route only until oral therapy can be administered:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months, Children, and Adolescents weighing &lt;30 kg: 120 mg/m<sup>2</sup>/dose every 6 hours; maximum dose: 160 mg/dose (Retrovir prescribing information [Canada] 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;30 kg: 1 to 2 mg/kg every 4 hours around the clock (Retrovir prescribing information [Canada] 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 perinatal transmission, prevention </b>(HHS [perinatal] 2017): Zidovudine dosing should begin as soon as possible after birth (within 6 to 12 hours after delivery). For patients at high risk of HIV acquisition, a 2- or 3-drug regimen may be needed. If infant is diagnosed as HIV positive, discontinue prevention (prophylaxis) dosing and begin a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants born prematurely (GA &lt;35 weeks): Refer to Dosing: Neonatal; standard infant doses may be excessive in infants who were born prematurely</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 weeks (GA &ge;35 weeks) (HHS [perinatal] 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Usual duration is 4 to 6 weeks. The shorter 4-week course is recommended if the mother received standard combination antiretroviral therapy during pregnancy, viral suppression was sustained, and maternal adherence is not a concern.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fixed weight-band dosing regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">2 to &lt;3 kg: 10 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">3 to &lt;4 kg: 15 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">4 to &lt;5 kg: 20 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 3 mg/kg/dose every 12 hours. <b>Note:</b> Use IV route only until oral therapy can be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016): <b>Note:</b> Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants (PCA &ge;35 weeks and PNA &ge;4 weeks of age) and Children: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">4 to &lt;9 kg: 12 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">9 to &lt;30 kg: 9 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Patients should receive IV therapy only until oral therapy can be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 mg/kg/dose administered every 4 hours around-the-clock</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perinatal HIV-1 transmission, prevention:</b> Maternal dose: <b>Note:</b> Zidovudine should be administered by continuous IV infusion during labor and delivery regardless of antepartum regimen or mode of delivery in women with HIV RNA &gt;1,000 copies/mL or unknown HIV RNA status. If oral zidovudine was part of the antepartum regimen, discontinue during intrapartum IV infusion. Other antiretroviral agents should be continued orally. Zidovudine IV is not required in women receiving combination antiretroviral therapy who have HIV RNA &le;1,000 copies/mL consistently in late pregnancy and/or near delivery and have no adherence or tolerance concerns (HHS [perinatal] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (preferred route): During labor and delivery: Loading dose: 2 mg/kg followed by a continuous IV infusion of 1 mg/kg/hour until delivery. For scheduled cesarean delivery, begin IV zidovudine 3 hours before surgery. In cases of unscheduled cesarean delivery due to maternal and fetal indications, consider administering the loading dose then proceeding to delivery.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (if IV not possible): Loading dose: 600 mg, then 400 mg every 3 hours (oral is not the preferred route of administration in the United States)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;6 weeks, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on oral doses of 160 mg/<b>m<sup>2</sup></b>/dose every 8 hours and IV dose of 120 mg/<b>m<sup>2</sup></b>/dose every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): Administer 50% of dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Administer 50% of dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;15 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">End-stage renal disease patients (CrCl &lt;15 mL/minute) and patients receiving hemodialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 100 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AIDS<i>info</i> guidelines: 100 mg every 8 hours or 300 mg once daily (HHS [adult] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 mg/kg/dose every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 100 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1 mg/kg/dose every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No adjustment needed (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment may be necessary due to extensive hepatic metabolism; dosage reduction may be required; use with caution; monitor for hematologic toxicities frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hematologic toxicity:</b> Consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or &gt;25% decrease from baseline) and/or significant neutropenia (ANC &lt;750 cells/mm<sup>3</sup> or &gt;50% decrease from baseline) until evidence of bone marrow recovery occurs; once bone marrow recovers, dose may be resumed using appropriate adjunctive therapy (eg, epoetin alfa).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235125\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retrovir: 100 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retrovir: 10 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retrovir: 50 mg/5 mL (240 mL) [contains sodium benzoate; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235110\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056078\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV infusion: Administer over 1 hour; in neonates, dose may be infused over 30 minutes. Do not administer IM; do not administer IV push or by rapid infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133417\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235145\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Store undiluted vials at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light. When diluted in D5W, solution is physically and chemically stable for 24 hours at room temperature and 48 hours if refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Attempt to administer diluted solution within 8 hours if stored at room temperature or 24 hours if refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) to minimize potential for microbial-contaminated solutions (vials are single-use and do not contain preservative).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets, capsules, syrup: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect capsules from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056077\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents [Oral: FDA approved in ages &ge;4 weeks and adults; Injection (short-term use): FDA approved in adults] (<b>Note:</b> HIV regimens consisting of three antiretroviral agents are strongly recommended); chemoprophylaxis to reduce perinatal HIV-1 transmission [Oral, injection: FDA approved in ages 0 days to 6 weeks (postpartum therapy of HIV-1 exposed neonate) and adults (antepartum and intrapartum therapy of HIV-1 infected mother)]; has also been used as HIV nonoccupational postexposure prophylaxis (nPEP)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235211\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azidothymidine may be confused with azaTHIOprine, aztreonam </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Retrovir may be confused with acyclovir, ritonavir</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">AZT is an error-prone abbreviation (mistaken as azathioprine, aztreonam)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235208\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure (children), ECG abnormality (children), edema (children), left ventricular dilation (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, fatigue, headache, insomnia, irritability (children), malaise, nervousness (children), neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight loss (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation, diarrhea (children), dyspepsia, nausea (more common in adults), vomiting (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (most common in neonates; onset: 2 to 4 weeks), granulocytopenia (onset 6 to 8 weeks), macrocytosis (children), neutropenia (children), thrombocytopenia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly (children), increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auricular edema, ear redness, ear residue, debris or precipitate, otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Amblyopia, anaphylaxis, angioedema, anxiety, aplastic anemia, back pain, cardiomyopathy, confusion, decreased mental acuity, depression, diabetes mellitus, dizziness, dyschromia (blue pigmentation of nails and skin), dysgeusia, dyslipidemia, dyspnea, gynecomastia, hearing loss, hemolytic anemia, hepatitis, hepatomegaly with steatosis, hypersensitivity reaction, immune reconstitution syndrome, increased creatine phosphokinase, increased lactate dehydrogenase, insulin resistance, jaundice, lactic acidosis, leukopenia, lymphadenopathy, macular edema, mania, myopathy, myositis, oral mucosa hyperpigmentation, pancreatitis, pancytopenia (with marrow hypoplasia), paresthesia, photophobia, pruritus, pure red cell aplasia, redistribution of body fat, rhabdomyolysis, seizure, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis, tremor, urticaria, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235131\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potentially life-threatening hypersensitivity to zidovudine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Neutrophil count &lt;750/mm<sup>3</sup> or hemoglobin &lt;7.5 g/dL (4.65 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235114\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: <b>[US Boxed Warning]: Hematologic toxicity, including neutropenia and severe anemia have been reported with use, especially with advanced HIV-1 disease.</b> Toxicity may be related to duration of use and prior bone marrow reserve. Hemoglobin reduction may occur in as early as 2 to 4 weeks; neutropenia usually occurs after 6 to 8 weeks. Pancytopenia has been reported (usually reversible). Use with caution in patients with bone marrow compromise (granulocytes &lt;1,000 cells/mm<sup>3</sup> or hemoglobin &lt;9.5 mg/dL). Monitor blood counts; dose interruption may be required in patients who develop anemia or neutropenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases.</b> Risk may be increased with obesity or in females. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipoatrophy: May cause loss of subcutaneous fat, especially in the face, limbs, and buttocks. Lipoatrophy incidence and severity are related to cumulative exposure and may be only partially reversible; improvement may take months to years after switching to a regimen that does not contain zidovudine. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy:<b> [US Boxed Warning]: Prolonged use has been associated with symptomatic myopathy and myositis.</b> Pathological changes observed are similar to that produced by HIV-1 disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Hematologic toxicity may be increased due to increased serum concentrations in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with CrCl &lt;15 mL/minute; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Newborns: Zidovudine newborn prophylaxis may affect diagnostic virologic assays in HIV-exposed infants. If a virologic assay result is negative while the infant is receiving combination antiretroviral prophylaxis, repeat virologic testing should be considered 2 to 4 weeks after cessation of antiretroviral prophylaxis (HHS [pediatric] 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Latex is used in vial stopper. May cause allergic reactions in latex-sensitive individuals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819271\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in patients with ANC &lt;1,000 cells/mm<sup>3</sup> or hemoglobin &lt;9.5 g/dL; consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or reduction &gt;25% of baseline; neonates: Hgb &lt;7 g/dL) or neutropenia (ANC &lt;750 cells/mm<sup>3</sup> or reduction &gt;50% from baseline; neonates ANC &lt;500 cells/mm<sup>3</sup>); use of erythropoietin or filgrastim may be necessary in some patients. In perinatally HIV-exposed infants, the sensitivity of diagnostic virologic assays, particularly HIV RNA assays, may be affected by combination antiretroviral prophylactic therapy in the infant. Thus, a negative result of a diagnostic virologic assay should be repeated 2 to 4 weeks after cessation of neonatal combination antiretroviral prophylactic therapy. For infants at higher risk of perinatal HIV transmission, many experts recommend one test at 4 to 6 weeks of age with an additional test at 8 weeks of age (ie, 2 weeks after cessation of prophylaxis at 6 weeks of life) (HHS [pediatric] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235195\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor), OAT3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235119\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13007&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May decrease the metabolism of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the metabolism of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Zidovudine may enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Zidovudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235135\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Zidovudine has a high level of transfer across the human placenta; the placenta also metabolizes zidovudine to the active metabolite. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general, NRTIs are well tolerated and the benefits of use generally outweigh potential risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider zidovudine a component in alternative regimens for initial therapy in antiretroviral-na&iuml;ve pregnant females. Zidovudine should be administered IV near delivery regardless of antepartum regimen or mode of delivery in females with HIV RNA &gt;1,000 copies/mL or unknown HIV RNA status (even in cases of documented zidovudine resistance) and may be considered in females with HIV RNA between 50 to 999 copies/mL, unless there is a history of hypersensitivity. The pharmacokinetics of zidovudine are not significantly altered in pregnancy and dosing adjustment is not needed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056073\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, electrolytes, glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, signs of medication toxicity and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Lipid panel and urinalysis every 6 to 12 months. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, hepatotoxicity, anemia, or lactic acidosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235113\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Zidovudine is a thymidine analog which interferes with the HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication; nucleoside reverse transcriptase inhibitor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235130\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In general, pharmacokinetic data for pediatric patients &gt;3 months to 12 years of age are similar to data in adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Significant penetration into the CSF</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: 1 to 2.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF/plasma ratio:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 3 months to Children 12 years (n=38): Median: 0.68; Range: 0.03 to 3.25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults (n=39): Median: 0.6; Range: 0.04 to 2.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 25% to 38%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via glucuronidation to inactive metabolites, including GZDV; extensive first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Similar for tablets, capsules, and syrup</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &lt;14 days: 89%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 14 days to 3 months: 61%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 3 months to Children 12 years: 65%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 64% &plusmn; 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonate: 6.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term neonates: 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 14 days to 3 months: 1.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 3 months to Children 12 years: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.5 to 3 hours (mean 1.1 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 30 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Urine (72% to 74% as metabolites, 14% to 18% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Urine (45% to 60% as metabolites, 18% to 29% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235134\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Retrovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $323.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zidovudine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $79.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Retrovir Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $35.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Retrovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (240 mL): $77.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zidovudine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $360.97</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235138\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adovi (ID);</li>\n      <li>Antivir (TH);</li>\n      <li>Aviral (CO);</li>\n      <li>Avirzid (ID);</li>\n      <li>Azidomine (KR);</li>\n      <li>Kedu (CN);</li>\n      <li>Latus AZT (PY);</li>\n      <li>Retrovir (AE, AR, AT, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, GY, HK, HN, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KW, LB, LU, LY, MT, MY, NL, NZ, OM, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, UA, UY, VE, VN, YE, ZW);</li>\n      <li>Retrovir AZT (CL);</li>\n      <li>Retrovir-AZT (MX, PE);</li>\n      <li>Timivudin (MX);</li>\n      <li>Zido-H (ET, LK);</li>\n      <li>Zidovir (BD, ET, IN, LB, PY);</li>\n      <li>Zydowin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briars LA, Hilao JJ, and Kraus DM, &quot;A Review of Pediatric Human Immunodeficiency Virus Infection,&quot; <i>Journal of Pharmacy Practice</i>, 2004, 17(6):407-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &quot;Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,&quot; April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/\" target=\"_blank\">http://www.aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &quot;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&quot; April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Updated Guidelines for Antiretroviroal Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. Available at <a href=\"https://stacks.cdc.gov/view/cdc/38856\" target=\"_blank\">https://stacks.cdc.gov/view/cdc/38856</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated March 2017. Accessed July 18, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. <i>Infect Control Hosp Epidemiol</i>. 2013;34(9):875-892.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/23917901 /pubmed\" target=\"_blank\" id=\"23917901 \">23917901 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller BU, Jacobsen F, Butler KM, et al, &quot;Combination Treatment With Azidothymidine and Granulocyte Colony-Stimulating Factor in Children With Human Immunodeficiency Virus Infection,&quot; <i>J Pediatr</i>, 1992, 121(5 Pt 1):797-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1279153/pubmed\" target=\"_blank\" id=\"1279153\">1279153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Retrovir (zidovudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Retrovir canadian (zidovudine) [prescribing information]. Laval Quebec: ViiV Healthcare ULC; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Volberding PA, Lagakos SW, Koch MA, et al, &quot;Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection. A Controlled Trial in Persons With Fewer Than 500 CD4-Positive Cells Per Cubic Millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases,&quot; <i>N Engl J Med</i>, 1990, 322(14):941-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zidovudine-pediatric-drug-information/abstract-text/1969115 /pubmed\" target=\"_blank\" id=\"1969115 \">1969115 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach,&rdquo; 2010. Available at http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13007 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708846\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F235151\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F235152\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056074\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445305\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056067\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F235125\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F235110\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056078\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133417\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F235145\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056077\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F235211\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F235208\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F235131\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F235114\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819271\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F235195\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F235119\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F235135\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056073\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F235113\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F235130\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F235134\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F235138\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13007|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">Zidovudine: Drug information</a></li><li><a href=\"topic.htm?path=zidovudine-patient-drug-information\" class=\"drug drug_patient\">Zidovudine: Patient drug information</a></li></ul></div></div>","javascript":null}